Autoimmune Events From Checkpoint Inhibitors Often Demand Aggressive Treatment

Autoimmune reactions to immune checkpoint inhibitors (ICIs) in cancer patients referred to rheumatologists were generally more severe than previously reported in a German study, with corticosteroids alone frequently proving insufficient to control symptoms. The findings suggest that many ICI-induced rheumatic and autoimmune adverse events require escalation to second-line immunosuppressive agents. The results underscore the need for early rheumatology involvement and multidisciplinary management of immune-related adverse events in oncology patients receiving checkpoint immunotherapy.